Navigation Links
Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
Date:4/13/2009

dent and Chief Executive Officer of Prometheus. "Leveraging our core strengths, we intend to apply this business model to oncology, where there is an unmet need to guide the use of a growing number of targeted therapies. We believe these three molecular diagnostic tests can help oncologists personalize therapy and are ideally suited to lead our entry into the oncology market, while complementing our emerging internal oncology diagnostics program."

"We believe that with this agreement Rosetta has proven the great commercial value of its first three products, and has established itself as a leader in the development of novel, molecular diagnostic products based on microRNAs. We are delighted to enter into this comprehensive partnership with Prometheus," said Amir Avniel, President and Chief Executive Officer of Rosetta Genomics. "With Prometheus these tests now will be available across the U.S., and will be supported by an organization with a proven ability in diagnostic testing services and in launching new products."

About miRview(TM) mets

miRview(TM) mets is designed to accurately identify the primary tumor site in patients presenting with metastatic cancer, as well as in patients whose tumor has not been identified and consequently has been labeled Cancer of Unknown Primary (CUP). As metastases need to be treated according to their primary origin, accurate identification of the primary origin is critical for determining optimal treatment, enabling better patient outcomes. Current diagnostic methods to identify the origin of a metastasis include a range of costly, time-consuming and at times inefficient tests. miRview(TM) mets offers physicians a fast, accurate and easy-to-interpret diagnosis of the predicted primary origin.

About miRview(TM) squamous

Using a single microRNA, miRview(TM) squamous is designed to differentiate squamous from non-squamous non-small cell
'/>"/>

SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
2. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
3. Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests
4. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay
5. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
6. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
7. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
8. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
9. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
10. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
11. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015 Agena Bioscience TM today announced the ... a commercial and financial hub from which many biotech and ... laboratories in mainland China . ... global sales with almost sixty MassARRAY ® Systems installed ... will allow us to expand our reach and foster a ...
(Date:9/1/2015)... In nur zwei Jahren nach dem ... SHL Group schnell weltweit 3.000 Mitarbeiter erreicht. Diese ... dem Markt der injizierbaren Medikamente und ... von SHL wieder. Foto - ... in Design und Herstellung automatischer Injektoren und Pen-Injektoren ...
(Date:9/1/2015)... WAYNE, Pa. , Sept. 1, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced that researchers will be  presenting scientific data ... Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, ... in development, at PainWeek 2015 to ...
Breaking Medicine Technology:Agena Bioscience Opens Office in Shanghai, China 2SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 3Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 4Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 5Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 6
(Date:9/1/2015)... ... September 01, 2015 , ... Pharmaceutical ... different malignancies. Some options for cancer treatment are available belonging to various ... approach is necessary for effective treatment. Several molecules have been discovered out ...
(Date:9/1/2015)... ... 2015 , ... Virginia entrepreneur Marcella Ellis, CEO and founder ... firm’s success in the hair care and distribution industry through her combination of ... be providing “Look and learn” live demonstrations, as well as promoting her new ...
(Date:9/1/2015)... ... September 01, 2015 , ... PetPace, the provider ... vital signs and activity, today announced its integration with leading veterinary Practice Management ... widely-adopted veterinary hospital Practice Management Software packages in the US. Practice Management Software ...
(Date:9/1/2015)... ... 2015 , ... Zecurion, a leading developer of data loss prevention solutions, announced ... DLP developed specifically for Mac OS. , In June 2015, the company successfully completed ... security professionals had participated. The beta test done by the developer community enabled Zecurion ...
(Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading audit, ... being named a “Best of the Best” firm in the U.S., as well as ... “Best of the Best” in the U.S., selected exclusively on performance in specific areas ...
Breaking Medicine News(10 mins):Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Zecurion Announces Endpoint Security for Mac 2Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2
... one of them has developed a flesh eating disease; another ... ,Necrotising fasciitis (flesh eating disease) is a rare infectious, ultimately ... spent five weeks in the hospital, and is released now. ... to the officials that the tattooist has to improve the ...
... discovered a protein interaction that may explain how the ... in and featured on the cover of the current ... Huntington’s protein interacts with another protein to cause dramatic ... ,“Cholesterol is essential for promoting the connection network among ...
... could help in fighting cancer,// a recent study issued an ... prone to a relapse of caner in the following cases: ... stem cells are from a female donor. ,This second ... the original transplant. This is more pronounced in them than ...
... Gene Therapy has published the findings of the first ... dysfunction.// The finding shows that gene therapy negates the ... beneficial for months, and hence could be the most ... author Arnold Melman, M.D., professor and chair of the ...
... has shown, in India, a majority of married women are ... Therefore, there is a definite need for protective methods that ... male-controlled methods are not even 20 percent helpful. ,A ... by over-the-counter microbicides, which are gels, creams, films, or suppositories, ...
... been told that patients undergoing chemotherapy in remote areas may ... the patient sending a text of his symptoms according to ... means of a red alert sent to medical staff, or ... of new age technology may be used along with a ...
Cached Medicine News:Health News:Link Between Huntington’s and Abnormal Cholesterol Levels in Brain Establishe 2Health News:The Other Side of Hematopoietic Stem Cell Transplant 2Health News:Gene Therapy May Be the Solution for Erectile Dysfunction 2
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Anti Gliadin IgG Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum....
... Urinalysis WorkCell System - A Single ... per hour, with true load-and-go productivity ... Clinitek Atlas and UF-100 for complete ... systems working together deliver utmost reliability. ...
... is one of the 3 major naturally ... estrone). In terms of estrogenic activity, estriol ... Estriol is produced almost exclusively during pregnancy, ... the normal human fetus. During pregnancy, the ...
Medicine Products: